How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease?

被引:5
作者
Mcpherson, Stuart [1 ,2 ,3 ]
Dyson, Jessica K. [1 ,2 ,3 ]
Jopson, Laura [1 ]
Masson, Steven [1 ,2 ,3 ]
Patel, Preya [1 ]
Anstee, Quentin M. [1 ,2 ,3 ]
机构
[1] Freeman Rd Hosp, Newcastle Tyne Hosp NHS Fdn Trust, Liver Unit, Newcastle Upon Tyne NE7 7DN, England
[2] Newcastle Tyne Hosp NHS Fdn Trust, Newcastle NIHR Biomed Res Ctr, Newcastle Upon Tyne, England
[3] Newcastle Univ, Translat & Clin Res Inst, Fac Med Sci, Newcastle Upon Tyne, England
关键词
NAFLD; DIAGNOSIS;
D O I
10.1111/apt.18061
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Sequential use of non-invasive fibrosis tests (NITs) to identify patients with advanced hepatic fibrosis is recommended. However, it remains unclear how reliable clinicians are staging liver fibrosis using combinations of NITs. Aim: Our aim was to assess concordance between NIT-based 'clinician fibrosis assessment (CFA)' and histology in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and compare this with established algorithmic approaches. Methods: Six experienced hepatologists independently staged 230 MASLD patients for advanced fibrosis (F0-2 vs F3-4) using FIB-4, FIB-4+ELF, FIB-4+ vibration controlled transient elastography (VCTE; Fibroscan (TM)) and FIB-4+ELF+VTCE. Concordance between histology and CFA or algorithmic approaches were assessed. Results: A total of 230 patients were included (median age 54 [22-78] years; 55% female; median FIB-4 1.21 [IQR: 0.78-1.91]; ELF 9.3 [IQR: 8.6-10.2]; VCTE 9.4 [IQR: 6.3-14.3]; 41% F0-1, 22% F2, 21% F3 and 16% F4). Overall, area under the receiver operator curves for histologic F3-4 for the raw tests were 0.84 for FIB-4, 0.86 for ELF and 0.86 for VCTE. Concordance between the hepatologists was good (FIB4, kappa = 0.64; FIB-4+ELF, kappa = 0.70; FIB-4+VCTE, kappa = 0.69; FIB-4+ELF+VCTE, kappa = 0.70). Concordance between individual CFA and histology was variable, which was reflected in variability in sensitivity (44%-84%) and specificity (76%-94%). Concordance with histology was better when clinicians used NIT combinations. Purely algorithmic approaches, particularly sequential use of FIB-4 then VCTE, tended to perform better than the CFA. Conclusions: Adhering to the recommended algorithmic approaches using NITs to stage fibrosis tended to perform more accurately than less-structured clinician NIT-based assessments conducted by experienced hepatologists.
引用
收藏
页码:267 / 273
页数:7
相关论文
共 20 条
  • [1] Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review
    Abeysekera, Kushala W. M.
    Macpherson, Iain
    Glyn-Owen, Kate
    McPherson, Stuart
    Parker, Richard
    Harris, Rebecca
    Yeoman, Andrew
    Rowe, Ian A.
    Dillon, John F.
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (08): : 770 - 780
  • [2] Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD
    Canivet, Clemence M.
    Costentin, Charlotte
    Irvine, Katharina M.
    Delamarre, Adele
    Lannes, Adrien
    Sturm, Nathalie
    Oberti, Frederic
    Patel, Preya J.
    Decaens, Thomas
    Irles-Depe, Marie
    Fouchard, Isabelle
    Hermabessiere, Paul
    Roux, Marine
    Barthelon, Justine
    Cales, Paul
    Powell, Elizabeth E.
    de Ledinghen, Victor
    Boursier, Jerome
    [J]. HEPATOLOGY, 2023, 77 (03) : 920 - 930
  • [3] Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
    Davison, Beth A.
    Harrison, Stephen A.
    Cotter, Gad
    Alkhouri, Naim
    Sanyal, Arun
    Edwards, Christopher
    Colca, Jerry R.
    Iwashita, Julie
    Koch, Gary G.
    Dittrich, Howard C.
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 (06) : 1322 - 1332
  • [4] Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care
    Dillon, John F.
    Miller, Michael H.
    Robinson, Emma M.
    Hapca, Adrian
    Rezaeihemami, Mohsen
    Weatherburn, Christopher
    McIntyre, Paul G.
    Bartlett, Bill
    Donnan, Peter T.
    Boyd, Kathleen A.
    Dow, Ellie
    [J]. JOURNAL OF HEPATOLOGY, 2019, 71 (04) : 699 - 706
  • [5] Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    Eddowes, Peter J.
    Sasso, Magali
    Allison, Michael
    Tsochatzis, Emmanouil
    Anstee, Quentin M.
    Sheridan, David
    Guha, Indra N.
    Cobbold, Jeremy F.
    Deeks, Jonathan J.
    Paradis, Valerie
    Bedossa, Pierre
    Newsome, Philip N.
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : 1717 - 1730
  • [6] European Association for the Study of the Liver, 2021, J HEPATOL, V75, p659 689
  • [7] The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease
    Hardy, Timothy
    Wonders, Kristy
    Younes, Ramy
    Aithal, Guruprasad P.
    Aller, Rocio
    Allison, Michael
    Bedossa, Pierre
    Betsou, Fay
    Boursier, Jerome
    Brosnan, M. Julia
    Burt, Alastair
    Cobbold, Jeremy
    Cortez-Pinto, Helena
    Day, Chris P.
    Dufour, Jean-Francois
    Ekstedt, Mattias
    Francque, Sven
    Harrison, Stephen
    Miele, Luca
    Nasr, Patrik
    Papatheodoridis, George
    Petta, Salvatore
    Tiniakos, Dina
    Torstenson, Richard
    Valenti, Luca
    Holleboom, Adriaan G.
    Yki-Jarvinen, Hannele
    Geier, Andreas
    Romero-Gomez, Manuel
    Ratziu, Vlad
    Bugianesi, Elisabetta
    Schattenberg, Jorn M.
    Anstee, Quentin M.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2020, 98
  • [8] Design and validation of a histological scoring system for nonalcoholic fatty liver disease
    Kleiner, DE
    Brunt, EM
    Van Natta, M
    Behling, C
    Contos, MJ
    Cummings, OW
    Ferrell, LD
    Liu, YC
    Torbenson, MS
    Unalp-Arida, A
    Yeh, M
    McCullough, AJ
    Sanyal, AJ
    [J]. HEPATOLOGY, 2005, 41 (06) : 1313 - 1321
  • [9] Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group
    McPherson, Stuart
    Armstrong, Matthew J.
    Cobbold, Jeremy F.
    Corless, Lynsey
    Anstee, Quentin M.
    Aspinall, Richard J.
    Barclay, Stephen T.
    Brennan, Paul N.
    Cacciottolo, Tessa M.
    Goldin, Robert D.
    Hallsworth, Kate
    Hebditch, Vanessa
    Jack, Kathryn
    Jarvis, Helen
    Johnson, Jill
    Li, Wenhao
    Mansour, Dina
    McCallum, Mary
    Mukhopadhya, Ashis
    Parker, Richard
    Ross, Valerie
    Rowe, Ian A.
    Srivastava, Ankur
    Thiagarajan, Prarthana
    Thompson, Alexandra, I
    Tomlinson, Jeremy
    Tsochatzis, Emmanuel A.
    Yeoman, Andrew
    Alazawi, William
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (08): : 755 - 769
  • [10] Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
    McPherson, Stuart
    Hardy, Tim
    Dufour, Jean-Francois
    Petta, Salvatore
    Romero-Gomez, Manuel
    Allison, Mike
    Oliveira, Claudia P.
    Francque, Sven
    Van Gaal, Luc
    Schattenberg, Joern M.
    Tiniakos, Dina
    Burt, Alastair
    Bugianesi, Elisabetta
    Ratziu, Vlad
    Day, Christopher P.
    Anstee, Quentin M.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (05) : 740 - 751